Advertisement
UK markets close in 1 hour 40 minutes
  • FTSE 100

    7,965.18
    +33.20 (+0.42%)
     
  • FTSE 250

    19,888.25
    +77.59 (+0.39%)
     
  • AIM

    743.94
    +1.83 (+0.25%)
     
  • GBP/EUR

    1.1698
    +0.0029 (+0.25%)
     
  • GBP/USD

    1.2635
    -0.0003 (-0.02%)
     
  • Bitcoin GBP

    56,460.82
    +1,325.03 (+2.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,252.67
    +4.18 (+0.08%)
     
  • DOW

    39,740.56
    -19.52 (-0.05%)
     
  • CRUDE OIL

    82.41
    +1.06 (+1.30%)
     
  • GOLD FUTURES

    2,231.10
    +18.40 (+0.83%)
     
  • NIKKEI 225

    40,168.07
    -594.66 (-1.46%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,495.34
    +18.25 (+0.10%)
     
  • CAC 40

    8,212.97
    +8.16 (+0.10%)
     

U.S. FDA approves AstraZeneca's asthma drug

Nov 14 (Reuters) - Anglo-Swedish pharmaceutical firm AstraZeneca Plc (NYSE: AZN - news) on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older.

The asthma drug will be marketed under the name Fasenra in the United States.

Fasenra is under regulatory review in the EU, Japan and several other countries, the company said.